Owing to their overall safety and efficacy, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming the preferred therapeutic option for the management of both obesity and type 2 diabetes mellitus (T2DM) [12]. Here, GLP1R is linked to diabetes mellitus.